



# MPS PHARMAA LIMITED

(FORMERLY ADVIK LABORATORIES LIMITED)

---

**Dated: 02<sup>nd</sup> February, 2026**

**The Manager (Listing)  
BSE Limited  
01<sup>st</sup> Floor, P. J. Towers  
Dalal Street, Mumbai - 400001**

**Sub: Outcome of the Board Meeting and Submission of Standalone Un-audited Financial Results for the quarter & nine months ended 31<sup>st</sup> December, 2025**

**Ref: BSE Scrip Code 531686; ASE Scrip Code- 01636 (ADVIK LABO)**

**Dear Sir,**

This is to inform you that pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Monday, 02<sup>nd</sup> February, 2026 at 3:00 P.M. at the corporate office of the company situated at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001 and concluded at 04:45 P.M has inter-alia, transacted the following business:

1. Considered and Approved the Standalone Un-audited Financial Results of the Company for quarter & nine months ended 31<sup>st</sup> December, 2025.
2. Considered and Approved the Limited Review Report for the Standalone Un-audited Financial Results of the Company for quarter & nine months ended 31<sup>st</sup> December, 2025.

Further pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Standalone Un-audited Financial Results for the quarter & nine months ended 31<sup>st</sup> December, 2025 along with Limited Review Report thereon for the quarter & nine months ended 31<sup>st</sup> December, 2025 is enclosed herewith for your kind perusal.

Kindly take the aforesaid information in your records.

Thanking You.

Yours Truly,

**For MPS Pharmaa Limited  
(Formerly Advik Laboratories Limited)**

**Pooja Chuni  
Company Secretary**

**Encl: As above**

**CC:**

**The Manager (Listing)  
Ahmedabad Stock Exchange Limited  
01<sup>st</sup> Floor, Kamdhenu Complex  
Opp. Sahajanand College,  
Panjara Pole, Ambawadi, Ahmedabad - 380015**

---

**CIN No. : L74899HR1994PLC038300**

**Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001**

**Phones: 011-42424884, 43571040-45, Fax: 011-43571047**

**Regd. Office & Factory: 138. Roz-Ka-Meo Industrial Area, Sohna - 122103 (Distt.Mewat), Haryana**

**Phones: 0124-2362471 Email:info@mpspharmaa.com Website: www.mpspharmaa.com**



MPS PHARMAA LIMITED (FORMERLY ADVIK LABORATORIES LIMITED)							
Regd. Off. :138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat, Haryana - 122103							
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED							
DECEMBER 31, 2025							
CIN : L74899HR1994PLC038300							
(Rs in Lacs except EPS)							
Sr No	Particulars	For the Quarter ended			For the nine months ended		Year Ended
		31-Dec-25 (Unaudited)	30-Sep-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-25 (Audited)
<b>1</b>	<b>Income from Operation</b>						
	(a) Net Sales/Revenue from Operations	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
	(c) Other Income	-	-	4.38	-	4.77	4.77
	<b>Total Income</b>	-	-	<b>4.38</b>	-	<b>4.77</b>	<b>4.77</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of Materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-trade	-	-	-	-	-	-
	c) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade	-	-	-	-	-	-
	d) Employee Benefits Expenses	13.12	13.18	12.87	39.47	39.34	52.47
	e) Finance Costs	0.01	0.02	0.01	0.05	0.02	0.05
	f) Depreciation and Amortisation expense	3.67	3.67	3.67	11.01	11.01	14.68
	g) Other expenses	6.15	6.13	5.61	18.31	17.86	23.96
	<b>Total Expenses</b>	<b>22.95</b>	<b>23.00</b>	<b>22.16</b>	<b>68.83</b>	<b>68.23</b>	<b>91.16</b>
<b>3</b>	<b>Profit/(Loss) before Exceptional Items and tax (1-2)</b>	<b>(22.95)</b>	<b>(23.00)</b>	<b>(17.79)</b>	<b>(68.83)</b>	<b>(63.46)</b>	<b>(86.39)</b>
<b>4</b>	<b>Exceptional Items</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit/(Loss) before tax (3 + 4)</b>	<b>(22.95)</b>	<b>(23.00)</b>	<b>(17.79)</b>	<b>(68.83)</b>	<b>(63.46)</b>	<b>(86.39)</b>
<b>6</b>	<b>Tax Expense</b>						
	- Current tax	-	-	-	-	-	-
	- Deferred tax ( Income)/ expenses	(0.92)	(0.99)	(0.33)	(2.77)	(1.63)	0.03
	- Adjustment of MAT Credit of earlier years	-	-	-	-	-	3.38
	<b>Total Tax Expenses</b>	<b>(0.92)</b>	<b>(0.99)</b>	<b>(0.33)</b>	<b>(2.77)</b>	<b>(1.63)</b>	<b>3.40</b>
<b>7</b>	<b>Profit/(Loss) for the period ( 5-6)</b>	<b>(22.03)</b>	<b>(22.02)</b>	<b>(17.46)</b>	<b>(66.06)</b>	<b>(61.83)</b>	<b>(89.79)</b>
<b>8</b>	<b>Other Comprehensive Income (net of tax)</b>	0.33	0.33	0.29	1.00	0.87	1.33
<b>9</b>	<b>Deferred Tax Income/(Expenses)on OCI</b>	(0.08)	(0.08)	(0.08)	(0.26)	(0.23)	(0.35)
<b>10</b>	<b>Total Comprehensive Income for the period ( 7+8-9)</b>	<b>(21.78)</b>	<b>(21.76)</b>	<b>(17.25)</b>	<b>(65.32)</b>	<b>(61.19)</b>	<b>(88.81)</b>
<b>11</b>	<b>Paid-up equity share capital ( face value of Rs 10/- per share )</b>	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14
<b>12</b>	<b>Other Equity</b>						(1,803.07)
<b>13</b>	<b>Earning per share (EPS) of Rs 10/- each (not annualized)</b>						
	(1) Basic	(0.12)	(0.12)	(0.09)	(0.35)	(0.32)	(0.47)
	(2) Diluted	(0.12)	(0.12)	(0.09)	(0.35)	(0.32)	(0.47)

**NOTES:-**

- The above Financial Results for the quarter & nine months ended December 31, 2025 has been reviewed by the Audit Committee and thereafter approved by the Board of Directors & taken on record at its meeting held on February 02nd 2026. A Limited review of the same has been carried out by the Statutory Auditors.
- The Company operates in a single segment viz pharmaceuticals formulations and the results pertain to a single segment in accordance with IND AS 108-Operating Segment.
- The company has applied for renewal of its Drug Manufacturing Licences before the term of its expiry with the Food & Drugs Administration (FDA), Panchkula, for manufacturing pharmaceutical and allied products and the same is under consideration at the end of the FDA. The management of the company firmly believes that the company would be able to restart its business operations as the company is getting quotes from the prospective buyers & the management is of the opinion that the new deals would be finalized soon. Further, the management of the company is also exploring the market and business opportunities and is putting necessary efforts in this respect so that the operations of the company can be started again.



	<b>Auditor's Observations in Audit Report for the Financial year 2024-25 as updated as on 31st December 2025:-</b>
4	<p>a) The company had recorded the cost of the investment of Rs. 53.80 Lac at the cost of Acquisition value of the equity shares issued and had not determined the fair value as required by Ind AS. The shares were not made available for physical verification. Hence, we are unable to comment upon the physical existence and express an opinion on the value of investment recorded.</p> <p>b) The Capital work in Progress of Rs. 2.49 Crore has been stalled. The physical conditions of these assets under construction require technical evaluation to determine impairments or write offs, if any. However in view of the management the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required.</p>
5	<p><b>Our explanation to Auditor's Observation:-</b></p> <p>a. The company has misplaced/lost the share certificates of the investments made by it in unquoted equity shares of other companies during the shifting of its records. Hence the company is unable to locate its investments made in the unquoted equity shares as the same are not physically held by the company at present. Despite sending multiple requests to the companies in which it has made investments for issue of duplicate share certificates, the same have not yet been entertained and till date the company has not received any reply from these companies. In addition to this, the company is working towards determining the fair market value of its investments to ensure the compliance with IND AS in true letter and spirits.</p> <p>b. The company allocated funds for building an additional factory block &amp; for Godown to expand its operations, but due to technical and other reasons, construction had to be temporarily suspended. Management believes the suspension is temporary, and the under-construction assets are not obsolete. The company anticipates resuming construction activities soon and does not foresee the need for any provisions. Additionally, the company is receiving advances back from some vendors due to non-execution of deals.</p>
6	The Company has not paid the Annual Listing Fees (ALF) of the Bombay Stock Exchange Limited (BSE) since the financial year 2021-22. Consequently, BSE has initiated action against the Company and suspended trading of its scrip on the Exchange's trading platform. However, BSE has permitted trading in the Company's shares on a Trade-for-Trade basis, limited to the first trading day of every week, until the outstanding Annual Listing Fees are fully paid to the Exchange. The management of the company is making necessary efforts to arrange the required funds for the purpose of making the outstanding payments of BSE.
7	The aforesaid unaudited financial results for the quarter & nine months ended 31st December, 2025 will be available on the website of the company i.e., <a href="http://www.mpspharmaa.com">www.mpspharmaa.com</a>
8	Previous year/period figures have been regrouped/arranged, wherever necessary to make them comparable with the current period figure.

For and on behalf of Board of Directors of  
MPS Pharmaa Limited  
(Formerly Advik Laboratories Limited)

  
(Peeyush Kumar Aggarwal)  
Chairman  
DIN : 00090423



Place: New Delhi  
Date : 02/02/2026



**NEMANI GARG AGARWAL & CO.**

**CHARTERED ACCOUNTANTS**

1517, DEVIKA TOWER, 6, NEHRU PLACE, NEW DELHI- 110 019.

Camp Office: Ch. No.5, Kamadgirl Aptt., Kaushambi, Ghaziabad-201010

Br. Office: B-602, Silver Sands CHS, Piramal Nagar Goregaon (West), Mumbai – 400104

**Independent Auditors Review Report on Unaudited Standalone Financial Results of the company for the quarter and Nine Months ended December 31, 2025. (Pursuant to the Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015 as amended**

**The Board of Directors of**

**MPS Pharmaa Limited (Formerly Advik Laboratories Limited)**

We have reviewed the accompanying statement of unaudited Standalone financial results of M/s MPS Pharmaa Limited (Formerly Advik Laboratories Limited) for the quarter and Nine Months ended December 31, 2025. ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Basis of Qualified Conclusion**

- a) *The company had recorded the cost of the investment of Rs. 53.80 Lac at the cost of Acquisition value of the equity shares Issued and had not determined the fair value as required by Ind AS. The shares were not made available for physical verification. Hence, we are unable to comment upon the physical existence and express an opinion on the value of investment recorded.*
- b) *The Capital work in Progress of Rs. 2.49 Crore has been stalled. The physical conditions of these assets under construction require technical evaluation to determine Impairments or write offs, if any. However in view of the management the suspension is temporary in nature and assets under construction are not obsolete, and the company will be able to resume construction activities in near future and accordingly no provision is required*

Tel.-0120-4374727 Mob.-9811026144 (SKN), 9223230576 (SNR),  
9810842989 (JMK), 9810893480 (DCK)  
Email ID: [nemani61@gmail.com](mailto:nemani61@gmail.com), [ngacodelhi@gmail.com](mailto:ngacodelhi@gmail.com)  
WebSite. : [sknemani.com](http://sknemani.com)



## Qualified Conclusion

Based on our review conducted as above, except for the matters described in the Basis of Qualified Conclusion above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

## Emphasis of Matter.

- 1. We draw attention to note no. 3 of Financial Result for the quarter ended December 31, 2025 regarding no Revenue from Operations during Nine Months ended December 31, 2025**
- 2. Company has not provided impact of New Labour Code notified on 21<sup>st</sup> November 2025 on Gratuity and Leave Encashment Provision.**

**Our Opinion is not modified in respect to Above Matter.**

For M/s. Nemani Garg Agarwal & Co.,  
Chartered Accountants  
FRN: 010192N



(J.M. Khandelwal)  
Partner  
M. No. 074267  
Udin:  
Place : New Delhi  
Date :02.02.2026



UDIN :- 26074267RHEHQY3217